AzddMeC

Category	Human immunodeficiency Virus (HIV)
CAS	87190-79-2
Description	Az-Dcme is a RNA-directed DNA polymerase inhibitor potentially for the treatment of HIV infection.

Quotation Now

Product Information

Synonyms	Az-Dcme; 3'-Azido-2',3'-dideoxy-5-methylcytidine; AZ-5MeC; 3'-N3-5-Me-ddC; CS-92
IUPAC Name	4-amino-1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidin-2-one
Molecular Weight	266.26
Molecular Formula	C10H14N6O3
Canonical SMILES	CC1=CN(C(=O)N=C1N)C2CC(C(O2)CO)N=[N+]=[N-]
InChI	InChI=1S/C10H14N6O3/c1-5-3-16(10(18)13-9(5)11)8-2-6(14-15-12)7(4-17)19-8/h3,6-8,17H,2,4H2,1H3,(H2,11,13,18)/t6-,7+,8+/m0/s1
InChIKey	GZSDAHQGNUAEBC-XLPZGREQSA-N
Purity	>98.00%
Solubility	In Vitro: DMSO : 200 mg/mL(751.15 mM;Need ultrasonic)
Appearance	Solid powder
Storage	Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Complexity	496
Exact Mass	266.112732
In Vitro	AzddMeC (CS-92) is effective against HIV-2 in lymphocytes. The replication of Friend murine virus is only weakly inhibited, and no effect is observed against HSV type 1 and type 2 and coxsackievirus B4. The interaction of the 5'-triphosphate of AzddMeC with HIV-1 reverse transcriptase indicated competitive inhibition (the inhibition constant, Kis, is 9.3 nM).
In Vivo	The pharmacokinetics of AzddMeC are characterized following intravenous and oral administration of 60 mg/kg of the compound to male rhesus monkeys. 3'-azido-3'-deoxythymidine (AZT) is a major metabolite of AzddMeC in monkeys. AzddMeC concentrations in serum declined rapidly in a biexponential fashion with the terminal half-life ranging from 0.5 to 1.3 hr. Renal excretion of unchanged nucleoside and Metabolic deamination yielding AZT are the primary routes of AzddMeC clearance. The oral bioavailability is 26%.
PSA	141.11000
Target	HIV; Reverse Transcriptase; Nucleoside Antimetabolite/Analog
XLogP3-AA	-0.3